Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - ObsEva (Details)

v3.22.4
Licensing and Other Arrangements - ObsEva (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 21, 2022
Dec. 31, 2022
Dec. 31, 2021
Asset acquisition      
Upfront cash payment to acquire assets   $ 15,247  
Reduction of contingent refund liability     $ 105
Estimated useful life of intangible asset 17 years    
Amortization expense   97  
Revenue recognized   4,150 $ 36,518
License Agreement | Organon      
Asset acquisition      
Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones $ 475,000    
ObsEva IP      
Asset acquisition      
Upfront cash payment to acquire assets 15,000    
Cost to acquire assets 15,200    
Transaction costs $ 200    
Estimated useful life of intangible asset 17 years    
Amortization expense   100  
Impairment of intangible asset   0  
ObsEva IP | License Agreement      
Asset acquisition      
Maximum earn-out payments $ 97,500    
Maximum earn-out payments for development and regulatory milestones 46,500    
Maximum earn-out payments for sales-based milestones $ 51,000    
Contract assets   0  
Contract liabilities   0  
Revenue recognized   $ 0